ProMIS Neurosciences
@ProMISinc
ProMIS is focused on development of antibody therapeutics targeting toxic proteins implicated in Alzheimer’s, ALS and multiple system atrophy. NASDAQ:PMN
You might like
Neurology Today and ANN, thank you for the opportunity to discuss science. Dr. Kaplan said the Abeta vaccine differs from other development because it “is selective for toxic oligomers and does not contain Abeta T-cell epitopes, so it will not stimulate detrimental T cells."
Via #AANAM: A vaccine targeting abeta oligomers to inhibit progression of #Alzheimers disease produced a strong antibody response in mice without inducing any measurable inflammatory response: bit.ly/3L4spSh #neurotwitter #dementia @AANMember @ProMISinc @TWisniewskiMD
Antibodies that bind selectively to neurotoxic Aβ oligomers potentially modify the course of the Alzheimer's disease. biospace.com/article/bridgi…
On Nov 14th we shared third quarter 2022 financial results and highlighted recent developments. promisneurosciences.com/investors #Alzheimers #ENDALZ $PMN
Our #drugdiscovery platform combines #biology, #physics and #supercomputing to neutralize toxic amyloid with a precision that traditional #drugdevelopment tools can't achieve. Data show no monomer distraction. bit.ly/3RUQ7BN #TechTuesday #biotech #ENDALZ
ProMIS has an important point of #differentiation. Our platform enables us to develop #antibodies that are highly selective for toxic misfolded #proteins. #Physics + #Biology + #Supercomputing. $PMN #differentiated #toxicoligomers #misfoldedproteins #neurodegenerativedisease
"Antibodies that target amyloid latch on at slightly different places.” #Lecanemab binds to protofibrils. “...before these chains clump together to form plaques in the brain. It could be that catching the amyloid earlier in the process makes a difference." cnn.it/3rFQPYE
We’re thrilled to announce Dr. Gail Farfel as our CEO. She brings more than 20 years’ experience in #neuropsychiatric clinical development & global regulatory submissions, including multiple successful #IND and #NDA apps & #FDA Advisory experience $PMN bit.ly/3CbURhN
Heartiest congratulations to @EisaiUS , #Biogen, its clinical trial researchers and most importantly, the clinical trial volunteers who committed their time and trust to deliver landmark news for the #Alzheimer's community. ##WorldAlzheimersMonth #ENDALZ bit.ly/3y2yF7k
PMN310 distinguishes itself from other Aß-directed antibodies by its enhanced selectivity for toxic oligomers (negligible binding to monomers and plaque) along with its ability to withstand competition by abundant monomers $PMN #ourpromis
Our highly selective antibodies target the toxic forms of proteins, leaving the normal forms that are essential for healthy brain and neuronal functions unaffected $PMN #exquisiteselectivity #toxicoligomers
Dr. Gail Farfel has been appointed CEO of ProMIS Neurosciences. Dr. Farfel brings 25 years of experience and a successful track record in neurological and neuropsychiatric drug development bit.ly/3DCLfhh $PMN #CEO #alzheimersdisease #endALZ
Our lead candidate, PMN310 for Alzheimer’s disease, selectively targets the soluble Aβ oligomers and does not bind to amyloid plaques. We expect this to reduce the risk of ARIA and potentially allow for the safe administration of higher doses $PMN
We are proud to support the Equity in Neuroscience & Alzheimer’s Clinical Trials (ENACT) Act! This bill would increase participation of underrepresented communities in dementia clinical trials. Learn more and take action: p2a.co/xuOMRgm. #ENACTAct #ENDALZ
What is protein misfolding? A normal protein folds into a specific shape to perform its function. Misfolded proteins, or toxic oligomers, have a different shape which exposes toxic portions, leading to pathological mechanisms of disease and death of neurons $PMN #stockstowatch
Our technology leverages advances in neurodegeneration enabled by computational modeling power, allowing us to develop highly selective antibodies that target the misfolded, toxic forms of proteins $PMN
Today we announced ProMIS’s second quarter 2022 financial results and program developments bit.ly/3ArUz5z $PMN #financialresults #stockmarket #investors #Q2 #promisneurosciences
We are pioneering the new field of protein misfolding disease. Our advisory boards comprise specialists in Alzheimer’s and neurodegenerative diseases along with experts in product development, and monoclonal antibody design and manufacturing $PMN
We are leveraging our patented technology to build a portfolio of candidate antibodies, vaccines, and diagnostics to combat neurodegenerative diseases including Alzheimer’s disease, MSA, Parkinson’s disease and ALS $PMN
🧠 Dr. Neil Cashman of @DMCBrainHealth and @ProMISinc is leading a team of Canadian neuroscientists working to develop a vaccine against #neurodegenerative diseases caused by the misfolded protein #AlphaSynuclein. Learn more: bit.ly/3OStbRV
#WesternU's @maximoprado is part of a team working on a vaccine against neurodegenerative diseases caused by the misfolded protein alpha-synuclein (A-syn). Led by Dr. Neil Cashman from @DMCBrainHealth, the project is supported by @WestonFamilyFdn. centreforbrainhealth.ca/news/new-colla…
United States Trends
- 1. Good Saturday 27K posts
- 2. #SaturdayVibes 4,025 posts
- 3. #Caturday 3,387 posts
- 4. #Varanasi 45.3K posts
- 5. Massie 72.6K posts
- 6. #MeAndTheeSeriesEP1 650K posts
- 7. PONDPHUWIN AT MAT PREMIERE 517K posts
- 8. Draymond 25.7K posts
- 9. #askdave N/A
- 10. IT'S GAMEDAY 2,351 posts
- 11. Marjorie Taylor Greene 66.1K posts
- 12. Michelle 60.4K posts
- 13. Wemby 48.9K posts
- 14. Bubba 66.3K posts
- 15. For God 184K posts
- 16. Steph 89.6K posts
- 17. Liz Cheney 4,698 posts
- 18. The View 92.3K posts
- 19. Charlie Brown 3,002 posts
- 20. MIGA 16.6K posts
You might like
Something went wrong.
Something went wrong.